Physician profile
Daniel Devries
NPI 1659937381
$3,106.36
in general payments reported to CMS, 2019-2025
28 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $542 · 2023: $615 · 2024: $844 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Consulting Fee: $27.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.26 |
| Consulting Fee | $27.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $595.36 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $334.37 | 2022-2024 | |
| Medtronic, INC. | $284.08 | 2023-2025 | Hawkone, Linq II |
| Pfizer INC. | $216.25 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $178.63 | 2022-2024 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.45 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $176.96 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.60 | 2022-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $125.88 | 2025 | |
| Heartflow, INC. | $108.00 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.19 | 2022-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $96.34 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $70.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $70.46 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $63.82 | 2022-2025 | Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $62.96 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $58.80 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $40.87 | 2023 | Arcalyst |
| Baxter Healthcare | $27.06 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $25.23 | 2024 | Onpattro |
| Abbott Laboratories | $23.60 | 2025 | Viewmate |
| Sanofi-Aventis U.S. LLC | $22.09 | 2024 | |
| Philips North America LLC | $21.32 | 2025 | Holter |
| Cvrx, INC. | $20.82 | 2025 | Barostim Neo System |
| Cleerly, INC. | $17.21 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Lilly USA, LLC | $16.91 | 2025 | Zepbound |
| Scpharmaceuticals INC. | $15.52 | 2025 | |
| Atricure, INC. | $14.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.